Venous thromboembolism in hospitalized children has long existed in a clinical gray zone — clinicians managing at-risk pediatric patients have had to extrapolate from adult data or rely on institutional practice variation rather than evidence-based consensus. That gap begins to close with the release of joint ASH/ISTH guidelines specifically addressing anticoagulant prophylaxis in pediatric populations, a milestone that could meaningfully standardize care across hematology and critical care settings.
Developed by a multidisciplinary panel using the GRADE framework — which formally rates the certainty of evidence behind each recommendation — the guidelines synthesize systematic evidence reviews conducted through April 2025. The panel arrived at 12 recommendations, with notable attention to subgroups including children with solid cancers and those with chronic medical conditions. The process was notable for incorporating a patient representative, a methodological inclusion that reflects growing recognition that pediatric guideline panels must account for the lived experience of patients and caregivers navigating prophylaxis decisions. The panel explicitly flags the scarcity of high-quality trial data as a central constraint across most recommendations.
The clinical significance here is real but bounded by important caveats. Pediatric VTE incidence, while lower than in adults, carries outsized morbidity relative to the age group, and hospitalized children — particularly those with central venous catheters, malignancy, or congenital heart disease — face markedly elevated risk. The field has lacked validated, pediatric-specific VTE risk assessment models analogous to the Padua or Caprini scores used in adults. These guidelines acknowledge that gap directly, naming risk model development and validation as a top research priority. Most recommendations are likely conditional rather than strong given the evidence base, meaning they reflect expert judgment under uncertainty more than replicated trial data. For now, this document is best understood as an important consensus scaffold — not a definitive evidentiary mandate — that should reduce unjustified practice variation while catalyzing the targeted trials pediatric hematology urgently needs.